Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma

2004815 citationsJournal Article

Authors

David F. McDermott · Dana-Farber Cancer Institute

Meredith M. Regan · Beth Israel Deaconess Medical Center

Joseph I. Clark · Beth Israel Deaconess Medical Center

Lawrence E. Flaherty · City Of Hope National Medical Center

Geoffrey R. Weiss · University of Illinois Chicago

Theodore F. Logan · Beth Israel Deaconess Medical Center

John M. Kirkwood

Abstract

This randomized phase III trial provides additional evidence that HD IL-2 should remain the preferred therapy for selected patients with metastatic renal cell carcinoma.

Topics & Keywords

Renal cell carcinoma treatment Cancer Immunotherapy and Biomarkers Cancer Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 23, Issue 1, pp. 133-141

DOI: 10.1200/jco.2005.03.206

Field-Weighted Citation Impact: 37.88